ExeVir Bio: Funding, Investors & Team (Sep 2026)
ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. The company is harnessing a llama-derived antibody technology platform to generate robust antiviral therapies providing broad protection against coronaviruses. They using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat. ExeVir Bio develops a rapid response platform for antivirals. This platform technology enables an agile response to new health threats thanks to its short throughput time to generate drug candidates. The resulting protein-based therapeutics are sufficiently stable and easy to produce at a reasonable cost to enable true global access. ExeVir Bio was founded in 2020 and is headquartered in Zwijnaarde, Belgium.
ExeVir Bio has raised $42.0M across 1 funding round on record, the most recent an undisclosed round of $42.0M announced in Jul 2020.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ExeVir Bio Company Profile and Key Stats
Latest funding round on record: Jul 2020.
ExeVir Bio Funding Rounds
ExeVir Bio Founders and Leadership Team
No contact details are on record for this team yet.
ExeVir Bio Funding Compared to Other Biotechnology Startups
ExeVir Bio's latest round of $42.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ExeVir Bio in Biotechnology and Zwijnaarde
Companies Similar to ExeVir Bio
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…
ExeVir Bio Funding FAQs
What does ExeVir Bio do?
ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. The company is harnessing a llama-derived antibody technology platform to generate robust antiviral therapies providing broad protection against coronaviruses. They using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat. ExeVir Bio develops a rapid response platform for antivirals. This platform technology enables an agile response to new health threats thanks to its short throughput time to generate drug candidates. The resulting protein-based therapeutics are sufficiently stable and easy to produce at a reasonable cost to enable true global access. ExeVir Bio was founded in 2020 and is headquartered in Zwijnaarde, Belgium.
How much funding has ExeVir Bio raised?
ExeVir Bio has raised $42.0M across 1 round on record. The most recent is an undisclosed round of $42.0M announced in Jul 2020.
When did ExeVir Bio last raise funding?
ExeVir Bio's most recent funding round on record is an undisclosed round of $42.0M, announced in Jul 2020.
Who is the CEO of ExeVir Bio?
Torsten Mummenbrauer is listed as CEO at ExeVir Bio.
Where is ExeVir Bio headquartered?
ExeVir Bio is based in Zwijnaarde, Oost-Vlaanderen, Belgium.
How many employees does ExeVir Bio have?
ExeVir Bio is in the 11-50 employee band.
How does ExeVir Bio's funding compare to other Biotechnology startups?
ExeVir Bio's latest round of $42.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ExeVir Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ExeVir Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.